esorubicin has been researched along with Cancer of Pancreas in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fleming, TR; Salmon, SE; Vaughn, CB | 1 |
| Blayney, DW; Carr, BI; Doroshow, JH; Goldberg, DA; Leong, LA | 1 |
| Blayney, D | 1 |
1 trial(s) available for esorubicin and Cancer of Pancreas
| Article | Year |
|---|---|
Phase II evaluation of esorubicin (4'deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Doxorubicin; Drug Evaluation; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Pancreatic Neoplasms; Risk Factors | 1990 |
2 other study(ies) available for esorubicin and Cancer of Pancreas
| Article | Year |
|---|---|
Phase II trial of esorubicin in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Agents; Doxorubicin; Female; Heart Diseases; Humans; Male; Middle Aged; Pancreatic Neoplasms | 1986 |
Cardiotoxicity associated with 4'-deoxydoxorubicin.
Topics: Antibiotics, Antineoplastic; Doxorubicin; Female; Heart; Humans; Middle Aged; Pancreatic Neoplasms | 1986 |